|23rd April 2020||Robert Grant Edwards||2,609||Grant/award etc.||$0.00|
|23rd April 2020||Poggetto John Dal||3,086||Grant/award etc.||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.
Sonoma Pharmaceuticals, Inc. engages in identifying, developing, and commercializing therapies for chronic skin conditions. The company offers solutions in dermatology, animal healthcare, and advanced tissue care product areas. Its products target skin diseases including acne, atopic dermatitis, scarring, infections, itch, pain, and harmful inflammatory responses.